Contents

Preface XIII
List of Contributors XVII

Part I General Aspects 1

1 Serendipitous Target-Based Drug Discoveries 3
   János Fischer and David P. Rotella
   1.1 Introduction 3
   1.2 Recent Examples of Target-Based Drug Discovery 4
   1.3 Serendipitous Target-Based Drug Discoveries 7
   1.4 Drospirenone (Contraceptive with Anti-aldosterone Activity) 7
       1.4.1 Summary of Drospirenone Discovery 8
   1.5 Escitalopram (Selective Serotonin Reuptake Inhibitor Antidepressant) 9
       1.5.1 Summary of the Escitalopram Discovery 11
   1.6 Ezetimibe (Inhibitor of Cholesterol Absorption) 11
       1.6.1 Summary of Ezetimibe Discovery 13
   1.7 Lamotrigine (Discovery of a Standalone Drug for the Treatment of Epilepsy) 13
       1.7.1 Summary of Lamotrigine Discovery 15
   1.8 Omeprazole (Proton Pump Inhibitor Acid-Suppressive Agent) 15
       1.8.1 Summary of Omeprazole Discovery 16
   1.9 Outlook 17
   Acknowledgments 17
   List of Abbreviations 17
   References 18

2 Drug Discoveries and Molecular Mechanism of Action 19
   David C. Swinney
   2.1 Introduction 19
   2.2 Mechanistic Paradox 19
   2.3 Molecular Mechanism of Action 20
2.3.1  The Primary Driver of an Optimal MMOA is the Potential for 
Mechanism-Based Toxicity 22
2.3.2  Details of MMOA are not Captured by IC\textsubscript{50} and K\textsubscript{i} 22
2.3.3  Metrics, Biochemical Efficiency 24
2.4  How MMOAs were Discovered 25
2.4.1  MMOAs of Medicines Approved by the USFDA Between 1999 and 
2008 27
2.5  Case Study: Artemisinin 30
2.6  Summary 31
List of Abbreviations 32
References 32

Part II  Drug Class 35

3  Insulin Analogs – Improving the Therapy of Diabetes 37
John M. Beals
3.1  Introduction 37
3.2  Pharmacology and Insulin Analogs 38
3.3  Chemical Description 39
3.4  Rapid-Acting Insulin Analogs (Prandial or Bolus Insulin) 41
3.5  Long-Acting Insulin Analog Formulations (Basal Insulin) 48
3.6  Conclusions and Future Considerations 54
List of Abbreviations 55
References 55

Part III  Case Histories 61

4  The Discovery of Stendra\textsuperscript{TM} (Avanafil) for the Treatment of Erectile 
Dysfunction 63
Koichiro Yamada, Toshiaki Sakamoto, Kenji Omori, and Kohei Kikkawa
4.1  Introduction 63
4.2  Discovery of Avanafil 65
4.2.1  Differentiation Strategies to Develop a New Drug 65
4.2.2  Discovery of Isoquinoline Derivatives from Isoquinolinone Lead 65
4.2.3  Scaffold-Hopping Approaches from the Isoquinoline Leads 67
4.2.3.1  Monocyclic Type A Series: Tetrasubstituted Pyrimidine 
Derivatives 68
4.2.3.2  Monocyclic Type B Series: Trisubstituted Pyrimidine 
Derivatives 68
4.2.3.3  SAR of Substitution at the 2-Position of the Pyrimidine Ring (15) 70
4.2.3.4  SAR of Substitution at the 4-Position of the Pyrimidine Ring (16) 70
4.2.3.5  SAR of Substitution at the 5-Position of the Pyrimidine Ring 
(19, 20) 73
4.2.3.6  Core Structure Modifications of the Pyrimidine Nucleus of 
Avanafil 73
4.3 Pharmacological Features of Avanafil
  4.3.1 PDE Inhibitory Profiles
  4.3.2 In Vivo Pharmacology
  4.3.2.1 Potentiation of Penile Tumescence in Dogs
  4.3.2.2 Influence on Retinal Function in Dogs
  4.3.2.3 Influence on Hemodynamics in Dogs
  4.3.2.4 Influence on Nitroglycerin (NTG)-Induced Hypotension in Dogs
4.4 Clinical Studies of Avanafil
4.5 Conclusion

List of Abbreviations
References

5 Dapagliflozin, A Selective SGLT2 Inhibitor for Treatment of Diabetes
William N. Washburn
  5.1 Introduction
  5.2 Role of SGLT2 Transporters in Renal Function
  5.3 O-Glucoside SGLT2 Inhibitors
  5.3.1 Hydroxybenzamide O-Glucosides
  5.3.2 Benzylpyrazolone O-Glucosides
  5.3.3 o-Benzylphenol O-Glucosides
  5.4 m-Diarylmethane C-Glucosides
  5.4.1 Synthetic Route
  5.4.2 Early SAR of C-Glucoside Based SGLT2 Inhibitors
  5.4.3 Identification of Dapagliflozin
  5.5 Profiling Studies with Dapagliflozin
  5.6 Clinical Studies with Dapagliflozin
  5.7 Summary
  List of Abbreviations
  References

6 Elvitegravir, A New HIV-1 Integrase Inhibitor for Antiretroviral Therapy
Hisashi Shinkai
  6.1 Introduction
  6.2 Discovery of Elvitegravir
  6.2.1 HIV-1 Integrase and Diketo Acid Inhibitors
  6.2.2 Monoketo Acid Integrase Inhibitors and Elvitegravir
  6.3 Conclusion
  List of Abbreviations
  References